Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Production / Operations Routine +

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

By The Northwire Desk — AI Analysis Jun 02, 2026 · 07:30 OPTI · 7.9 Optimi Health Corp.
Executive Summary
  • Optimi Health Corp. completed a GMP production run of its 5mg psilocybin finished drug product.
  • The company operates a fully vertically integrated manufacturing pipeline covering biomass cultivation, API extraction, encapsulation, and packaging under a Health Canada Drug Establishment Licence (DEL).
  • Finished capsules are commercially prescribed in Australia for treatment-resistant depression (TRD) under the Authorized Prescriber Scheme.
  • An updated bottling configuration has been rolled out to improve usability for prescribers and patients.
  • Remaining inventory from the production run is allocated to support upcoming clinical trials in the United States and Europe.
  • The facility features a Level 8 vault compliant with institutional security standards, authorized to store up to 20kg of psilocybin and ~2,000kg of biomass.
  • The company also supplies MDMA and psilocybin drug products to regulated international markets for patient access and clinical research.
Material Impact
  • The June 2 announcement is a direct follow-up to the May 26 milestone regarding the highest-purity natural psilocybin extract (~6%) and the May 29 regulatory expansion in Australia.
  • It confirms the operationalization of the company's vertically integrated manufacturing thesis, validating that the GMP facility can produce commercial-grade finished products at scale.
  • The allocation of inventory to US and European clinical trials demonstrates progress in diversifying revenue streams beyond the Australian market.
  • However, the news is incremental. It does not introduce new contracts, revenue jumps, or regulatory approvals that would materially alter the company's valuation. It is a routine execution update that confirms management's stated roadmap.
OPTI · Price
Company Overview
  • Optimi Health Corp. is a vertically integrated psychedelic pharmaceutical company focused on the manufacturing and supply of GMP-grade psilocybin and MDMA.
  • Flagship Project: 5mg naturally derived psilocybin capsules for treatment-resistant depression (TRD) and 40mg/60mg MDMA capsules for PTSD.
  • The company operates two 10,000 sq ft GMP-compliant facilities in British Columbia, Canada, holding a Health Canada DEL.
  • Commercial operations are currently anchored in Australia under the TGA's Authorized Prescriber Scheme, with expansion plans into the US and Europe.
Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory May 26, 2026 · 07:01

Optimi Health Manufacturing Milestone Validates Capital Raise But Nasdaq Uplifting Remains Primary Valuation Driver

Production / Operations